The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data
Rationale and objective
Two mechanisms underlie smoking cessation efficacies of α4β2* nicotinic acetylcholine receptor (nAChR) agonists: a “nicotine-like” agonist activity reduces craving by substituting for nicotine during a quit attempt, and a “nicotine-blocking” antagonist activity attenuates reinforcement by competing with inhaled nicotine during a relapse. To evaluate the contribution of each mechanism to clinical efficacy, we estimated the degree of agonist and antagonist activities of nicotine replacement therapy (NRT), varenicline, cytisine, and the discontinued nAChR agonists dianicline, ABT-418, ABT-089, CP-601927, and CP-601932, relative to the functional effects of nicotine from smoking.
Functional activities that occur in vivo with clinical doses were predicted from literature data on binding and functional potencies at the target α4β2 nAChR, as well as at α6β2* nAChRs, and from estimates of free drug exposures in human brain. Agonist activity is comprised of nAChR activation and desensitization, which were expressed as percentages of desensitization and activation by nicotine from smoking. Antagonist activity was expressed as the reduction in nAChR occupancy by nicotine during smoking in the presence of an agonist.
Comparisons with odds ratios at end of treatment suggest that extensive α4β2 and α6β2* nAChR desensitization combined with α6β2* nAChR activation at similar levels as nicotine from smoking is associated with clinical efficacy (NRT, varenicline, cytisine, ABT-418). Effective competition with inhaled nicotine for α4β2 and α6β2* nAChRs further improves clinical efficacy (varenicline). Other discontinued nAChR agonists have lower agonist and antagonist activities at α4β2 nAChRs and are inactive or less efficacious than NRT (dianicline, ABT-089, CP-601927, CP-601932).
Three pharmacological effects appear to be key factors underlying smoking cessation efficacy: the degree of activation of α6β2* nAChRs, desensitization of α4β2 and α6β2* nAChRs (agonist activity), and the reduction of nicotine occupancy at α4β2 and α6β2* nAChRs (antagonist activity). No single activity is dominant, and the level of smoking cessation efficacy depends on the profile of these activities achieved at clinical doses. While adequate agonist activity alone seems sufficient for a clinical effect (e.g., NRT, cytisine), clinical efficacy is improved with substantial competitive antagonism of α4β2 nAChRs, i.e., if the drug has a dual agonist-antagonist mechanism of action (e.g., varenicline).
Keywordsα4β2 nAChR agonists α6β2* nAChR agonists nAChR activation and desensitization Agonist-antagonist activities Smoking cessation NRT Varenicline Cytisine
The authors thank Drs. David Lawrence and Sarah Dubrava (Pfizer, New York and Groton, USA) for conducting the meta-analyses, Dr. Ellen Wang (Pfizer, New York, USA) for reviewing the pharmacokinetic sections, and Dr. Jotham Coe (Pfizer, Groton, CT, USA) and Dr. Daniel Bertrand (HiQScreen, Geneva, Switzerland) for sharing unpublished data on discontinued nAChR agonists.
Compliance with ethical standards
Conflict of interest
HR and RSH are former employees of Pfizer Inc., the manufacturer of varenicline.
HR received financial support for this publication from Pfizer. RSH declares no conflict of interest.
- Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE (2016) Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 387:2507–2520CrossRefGoogle Scholar
- Beckmann JS, Meyer AC, Pivavarchyk M, Horton DB, Zheng G, Smith AM, Wooters TE, McIntosh JM, Crooks PA, Bardo MT, Dwoskin LP (2015) r-bPiDI, an α6β2* nAChR nicotinic receptor antagonist, decreases nicotine-evoked dopamine release and nicotine reinforcement. Neurochem Res 40:2121–2130CrossRefGoogle Scholar
- Cahill K, Stevens S, Perera R, Lancaster T (2013) Pharmacological interventions for smoking cessation: an overview and network meta-analysis (review). Cochrane Database of Systematic Reviews Issue 5. Art. No.: CD009329Google Scholar
- Cahill K, Lindson-Hawley N, Thomas KH et al (2016) Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD006103Google Scholar
- Champtiaux N, Gotti C, Cordero-Erausquin M, David DJ, Przybylski C, Léna C, Clementi F, Moretti M, Rossi FM, le Novère N, McIntosh JM, Gardier AM, Changeux JP (2003) Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci 23(21):7820–7829CrossRefGoogle Scholar
- Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD, O'Neill BT (2005) Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474–3477CrossRefGoogle Scholar
- Coe JW, Rollema H, O’Neill BT (2009a) Case history: ChantixTM/ChampixTM (varenicline tartrate), a nicotinic acetylcholine receptor partial agonist as a smoking cessation aid. Annu Rep Med Chem 44:71–101Google Scholar
- Coe JW, Brooks PR, Wirtz MC et al (2009b) Low efficacy partial agonists of the α4β2 nicotinic acetylcholine receptor (nAChR). Does functional efficacy govern in vivo response? Poster 3.11, nicotinic receptor-based therapeutics: emerging frontiers in basic research & clinical science (Bertrand D, Gopalakrishnan M, Donnelly-Roberts D, Eds). Biochem Pharmacol 78(7):919CrossRefGoogle Scholar
- Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, Leonardon J, Avenet P, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Voltz C, Gardes A, Caille D, Perrault G, George P, Soubrie P, Scatton B (2003) SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 306(1):407–420CrossRefGoogle Scholar
- Courtney R, Walker N (2017) Cytisine versus varenicline for smoking cessation: two clinical trials from the Australian cytisine trialist group. Abstract SYM16C, SRNT Annual Meeting Florence, Italy. March 8–11, 2017. Available at http://c.ymcdn.com/sites/www.srnt.org/resource/resmgr/conferences/2017_annual_meeting/SRNT_2017_Abstract_Book__Web.pdf. Accessed 8 Sep 2017
- Damaj M, Carroll IF, Brek Eaton JB et al (2004) Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 66(675–682):2004Google Scholar
- Decker MW, Brioni JD, Sullivan JP et al (1994) (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)lsoxazole (ABT-418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Therap 270(1):319–328Google Scholar
- Decker MW, Bannon AW, Curzon P et al (1997) ABT-089 [2-methyl-3-(2-(S) pyrrolidinylmethoxy) pyridine dihydrochloride]: II. A novel Cholinergic channel modulator with effects on cognitive performance in rats and monkeys. J Pharmacol Exp Therap 283:247–258Google Scholar
- Falcone M, Ashare RL, Allen A et al (2016) No efficacy signals for ABT-089, a nicotinic receptor partial agonist: results of a proof-of-concept pilot study in treatment-seeking smokers. Poster 5–12, SRNT 21st Ann Mtg, Feb 25–28, 2015, Philadelphia, PA. Available at https://c.ymcdn.com/sites/srnt.site-ym.com/resource/resmgr/Conferences/Past_Annual_Meetings/SRNT_2015_Rapids_WEB.pdf Accessed 12 May 2017
- Fava M, Ramey T, Pickering E, Kinrys G, Boyer S, Altstiel L (2015) A randomized, double-blind, placebo-controlled phase 2 study of the augmentation of a nicotinic acetylcholine receptor partial agonist in depression: is there a relationship to leptin levels? J Clin Psychopharmacol 35(1):51–56CrossRefGoogle Scholar
- FDA Drug Safety Communication (2016) FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings https://www.fda.gov/Drugs/DrugSafety/ucm532221.htm Accessed Oct 2017
- Fiore MC, Jaén CR, Baker TB et al (2008) Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008. Available at https://www.ncbi.nlm.nih.gov/books/NBK63952/ Accessed 15 Jan 2017
- Gotti C, Guiducci S, Tedesco V, Corbioli S, Zanetti L, Moretti M, Zanardi A, Rimondini R, Mugnaini M, Clementi F, Chiamulera C, Zoli M (2010) Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area α6β2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. J Neurosci 30(15):5311–5325CrossRefGoogle Scholar
- Grady SR, Drenan RM, Breining SR, Yohannes D, Wageman CR, Fedorov NB, McKinney S, Whiteaker P, Bencherif M, Lester HA, Marks MJ (2010) Structural differences determine the relative selectivity of nicotinic compounds for native α4β2, α6β2*, α3β4* and α7-nicotine acetylcholine receptors. Neuropharmacology 58(7):1054–1066CrossRefGoogle Scholar
- Hurst RS, Rollema H, Shaffer CL et al (2012) Pharmacological profile of CP-601927 at neuronal nAChRs. Poster at 42nd Ann Mtg Soc Neuroscience, Poster 532.21/B48. Oct 16, 2012, New Orleans. Available at http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=0f3d6fdf-47ad-42d9-a1fb-5e9ff52c753f&cKey=2768c157-36ed-4962-a2c3-b9c788414e16&mKey=70007181-01c9-4de9-a0a2-eebfa14cd9f1. Accessed 10 June 2017
- Jeong SH, Newcombe D, Sheridan J, Tingle M (2017a) Measuring plasma cytisine concentrations, cigarette craving, withdrawal, smoking satisfaction and mood to investigate the concentration-effect relationship in smokers. Abstract SYM16A, p. 23. SRNT Annual Meeting Florence, Italy. March 8–11, 2017. Available at http://c.ymcdn.com/sites/www.srnt.org/resource/resmgr/conferences/2017_annual_meeting/SRNT_2017_Abstract_Book__Web.pdf Accessed 8 Sep 2017
- Jeong SH, Sheridan J, Newcombe D, Tingle M (2017b) Plasma concentrations of cytisine, a commercially available plant-based alkaloid, in healthy adult smokers taking recommended doses for smoking cessation. Xenobiotica:1–4. https://doi.org/10.1080/00498254.2017.1409916
- Lloyd GK, Wiliams M (2000) Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Therap 292:461–467Google Scholar
- Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE (2007) Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation. TiPS 28:316–325Google Scholar
- Rollema H, Shrikhande A, Ward K, Tingley III FD, Coe JW, O'Neill BT, Tseng E, Wang EQ, Mather RJ, Hurst RS, Williams KE, de Vries M, Cremers T, Bertrand S, Bertrand D (2010) Preclinical properties of varenicline, cytisine and dianicline, α4β2 nAChR partial agonists for nicotine dependence, translate to clinical efficacy. An in vitro and in vivo study. Brit J Pharmacol 160:334–345CrossRefGoogle Scholar
- Rose JE, Behm FM (2017) Combination varenicline/bupropion treatment benefits highly dependent smokers in an adaptive smoking cessation paradigm. Nic Tob Res 999–1002Google Scholar
- Shurtleff D, Hopp C, Ng H, Wolfe G (2017) The regulatory science of cytisine: results from pre-clinical CLP-regulated safety assessment. Abstract SYM16D, SRNT Annual Meeting Florence, Italy March 8–11, 2017. Available at http://c.ymcdn.com/sites/www.srnt.org/resource/resmgr/conferences/2017_annual_meeting/SRNT_2017_Abstract_Book__Web.pdf Accessed 8 Sep 2017
- Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321–327Google Scholar
- Stead LF, Perera R, Bullen C et al (2012) Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD000146Google Scholar
- Steinbach JH (1990) Mechanism of action of the nicotinic acetylcholine receptor. Novartis Foundation Symposia, Ciba Foundation Symposium 152, The Biology of Nicotine Dependence, Chapter 4, p. 53–67. Kelly J.S. John Wiley & Sons, Ltd, 1990Google Scholar
- Sullivan JP, Donnelly-Roberts D, Briggs CA et al (1997) ABT-089 [2-methyl-3-(2-(S)-pyrrolidinyl-methoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Therap 283:235–246Google Scholar
- Tennant FS Jr, Tarver AL (1984) Withdrawal from nicotine dependence using mecamylamine: comparison of three-week and six-week dosage schedules. NIDA Res Monogr 55:291–297Google Scholar
- Tennant FS Jr, Tarver AL, Rawson RA (1984) Clinical evaluation of mecamylamine for withdrawal from nicotine dependence. NIDA Res Monogr 49:239–246Google Scholar
- Tutka P, Zatoñski W (2006) Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol Reports 58:777–798Google Scholar
- Tutka P, Vinnikov D, Courtney RJ et al (2017) Cytisine for nicotine addiction treatment: an updated meta-analysis. Poster POS5–121, 23rd Ann Mtg Soc Res Nic Tob March 11, Florence, Italy. Available at http://c.ymcdn.com/sites/www.srnt.org/resource/resmgr/conferences/2017_annual_meeting/2017_SRNT_Rapids_Abstracts_W.pdf
- Wilens TE, Gault LM, Childress A, Kratochvil CJ, Bensman L, Hall CM, Olson E, Robieson WZ, Garimella TS, Abi-Saab WM, Apostol G, Saltarelli MD (2011) Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. J Am Acad Child Adolesc Psychiatry 50(1):73–84CrossRefGoogle Scholar